3-哌嗪-1,2-苯异唑 | 87691-89-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3-哌嗪-1,2-苯异唑
• 中文别名: 3-(1-哌嗪)-1,2-苯并异唑；3-哌嗪-1,2-苯并异噁唑；3-(1-哌嗪基)-1,2-苯并异恶唑
• 英文名称: 4(1,2-benzisoxazol-3-yl)piperazine
• 英文别名: 3-(1-piperazinyl)-1,2-benzisoxazole；3-(piperazin-1-yl)benzo[d]isoxazole；3-Piperazin-1-YL-1,2-benzisoxazole；3-piperazin-1-yl-1,2-benzoxazole
• CAS: 87691-89-2
• 化学式: C₁₁H₁₃N₃O
• 分子量: 203.244
• InChiKey: ZDFQBFVFCPABKQ-UHFFFAOYSA-N

物化性质

• 熔点：
  74-76℃
• 沸点：
  387.8±22.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（轻微）、DMSO（轻微、超声处理）
• 稳定性/保质期：
  按规定使用和贮存的不会分解，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 储存条件：
  请将药品存放在密闭、阴凉、干燥的地方。

反应信息

• 作为反应物：
  描述：

  3-哌嗪-1,2-苯异唑 在 盐酸 、 potassium carbonate 、 potassium iodide 作用下， 以 乙醇 、 乙腈 为溶剂， 反应 20.25h， 生成 4-<4-(1,2-benzisoxazol-3-yl)-1-piperazinyl>-1-(4-fluorophenyl)-1-butanone hydrochloride
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents

  摘要：

  Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens. Structure-activity relationships within the series are discussed. Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests. It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h. The compound's lack of typical neuroleptic-like effects in the rat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy. Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile. Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.

  DOI：

  10.1021/jm00153a010
• 作为产物：
  描述：

  水杨基羟肟酸 在 三乙胺 、 N,N'-羰基二咪唑 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 40.0h， 生成 3-哌嗪-1,2-苯异唑
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents

  摘要：

  Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens. Structure-activity relationships within the series are discussed. Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests. It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h. The compound's lack of typical neuroleptic-like effects in the rat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy. Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile. Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.

  DOI：

  10.1021/jm00153a010

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• [EN] OXINDOLE SUBSTITUTED PIPERAZINE DERIVATIVES<br/>[FR] DERIVES DE PIPERAZINE SUBSTITUES PAR UN OXINDOLE
  申请人：WARNER LAMBERT CO

  公开号：WO2004037820A1

  公开（公告）日：2004-05-06

  The invention relates to compounds of the formula (I), wherein Ar, A, R, R?1, R2, R3, R4 and R5¿ are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

  这项发明涉及公式（I）的化合物，其中Ar，A，R，R1，R2，R3，R4和R5在规范中定义，包含它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。
• CARBAZOLE DERIVATIVES ACTING ON 5-HT7 RECEPTOR
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20160244408A1

  公开（公告）日：2016-08-25

  Disclosed are carbazole derivatives and pharmaceutically acceptable salts thereof that act on the 5-HT 7 receptor. The carbazole derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for the 5-HT 7 serotonin receptor and antagonistic activities against the 5-HT 7 serotonin receptor. Further disclosed are pharmaceutical compositions including the compounds as active ingredients. The pharmaceutical compositions are useful as therapeutic and prophylactic agents for central nervous system diseases where antagonistic activities against 5-HT 7 are required, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, and smooth muscle-related diseases.

  揭示了对5-HT7受体起作用的咔唑衍生物及其药用盐。这些咔唑衍生物及其药用盐对5-HT7 5-羟色胺受体具有高结合亲和力，并具有对5-HT7 5-羟色胺受体的拮抗活性。此外，还披露了包括这些化合物作为活性成分的药物组合物。这些药物组合物可用作治疗和预防中枢神经系统疾病的药物，其中需要对5-HT7具有拮抗活性，如抑郁症、偏头痛、焦虑、疼痛、炎症性疼痛、神经痛、体温失调、昼夜节律失调、睡眠障碍和平滑肌相关疾病。
• [EN] N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES<br/>[FR] DERIVES DE PIPERIDINE ET DE PIPERAZINE N-SUBSTITUES
  申请人：WARNER LAMBERT CO

  公开号：WO2005066165A1

  公开（公告）日：2005-07-21

  This invention relates to compounds of the formula 1 wherein R1, R2, R7, R8, R9, U, V, Z, A, W, X, M, E, L, T and D are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.

  这项发明涉及式1的化合物，其中R1、R2、R7、R8、R9、U、V、Z、A、W、X、M、E、L、T和D的定义如规范中所述，包含它们的药物组合物以及它们在治疗中枢神经系统和其他疾病中的用途。
• [EN] PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION<br/>[FR] PIPÉRAZINE UTILISÉE EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS AGISSANT SUR LE RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE DE TYPE 5 (MGLUR5)
  申请人：WYETH CORP

  公开号：WO2009143404A1

  公开（公告）日：2009-11-26

  The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula (I); wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.

  本发明的教导涉及具有公式（I）的哌嗪代谢型谷氨酸受体5（mGluR5）负变构调节剂；其中构成变量如本文所述定义。本发明的教导还涉及制备这些化合物的方法，以及使用这些化合物治疗包括精神分裂症、偏执症、抑郁症、躁郁症和焦虑症等疾病和失调的方法。